Bioscience Equity Partners introduces the inaugural edition of The Lambda Quarterly, its quarterly research publication examining global life sciences capital markets, capital formation, sovereign investment and key sector developments.
Bioscience Equity Partners is pleased to publish the inaugural edition of The Lambda Quarterly, the firm’s quarterly research publication focused on global life sciences capital markets.
The publication was created to provide a structured view of the forces shaping capital allocation across the sector, including public and private markets, mergers and acquisitions, cross border licensing, sovereign capital and major regulatory developments. BEP states that The Lambda Quarterly will be published four times each year.
The Q1 2026 inaugural edition examines a period in which life sciences capital markets showed renewed activity alongside continued selectivity. The report considers developments across biotechnology IPOs, venture and private capital, pharmaceutical M&A, Greater China licensing activity and the increasing role of sovereign capital in global life sciences financing.
The edition is structured around three central research theses: the changing nature of the biotechnology IPO market, the growing role of sovereign capital in late private and early public financing, and the continued evolution of Greater China outbound licensing.
The report also includes dedicated analysis of oncology, cardiometabolic disease and neurology, together with regional perspectives covering the United States, Europe, Greater China, Japan, Korea, Australia and the Gulf Cooperation Council.
The Lambda Quarterly | Q1 2026
Global Life Sciences Capital Markets Review
First Quarter 2026 | Inaugural Edition
